Clinical-stage psychedelics biotech Reunion Neuroscience (NASDAQ: REUN) and MPM BioImpact have completed their announced plan of arrangement for MPM&rsq
Minneapolis Mayor Deprioritizes Psychedelics: 'We Should Be In The Business Of Helping People'
Minneapolis Mayor Jacob Frey recently signed an executive order effectively deprioritizing criminal prosecution for possession, use, purchase, cultivation and engaging in practices with “entheogenic plants or plant compounds."
As Reunion Neuroscience (NASDAQ: REUN) and Mindset Pharma (OTCMKTS: MSSTF) continue their court battle over claims on a novel 4-OH-DiPT prodrug, private biotech company Terran Biosciences has also filed a patent application over a proprietary polymorph,
Clinical-stage psychedelics company Reunion Neuroscience (NASDAQ: REUN) is about to close on its take-private transaction with MPM BioImpact affiliates, as shareholders voted for a special resolution approving the proposed arrangement plan on July 12.
https://www.marijuanamoment.net/california-psilocybin-legalization-campaign-cleared-to-collect-signatures-for-2024-ballot-initiative/
California officials have cleared a campaign to begin signature gathering for a 2024
https://www.marijuanamoment.net/bipartisan-lawmakers-push-for-marijuana-and-psychedelics-amendments-to-defense-bill-but-committee-action-is-delayed/Bipartisan lawmakers pushed for the adoption of marijuana and
Clinical-stage psychedelics firm Reunion Neuroscience Inc. (NASDAQ: REUN) reported fiscal results for the fourth quarter and year ended March 31 plus corporate updates.
Here's a breakdown of the report: